A new breakthrough originating from the University of Saskatchewan could potentially reduce the duration of the calving season for beef producers, which is typically the most labor-intensive period of their year. Cetrorelix, a hormone drug commonly utilized in human in vitro fertilization (IVF) procedures, is now being explored for potential applications in the cattle industry following successful research at the university in Saskatoon.
Dr. Jaswant Singh, a veterinary medicine expert and researcher at the Western College of Veterinary Medicine, discovered the effectiveness of Cetrorelix in a study unrelated to its current application around eight years ago. He acknowledges graduate students Dylan Farmer and Carlos Leonardi for their contributions to this innovation.
The drug functions as a method for synchronizing ovulation, prompting cows to conceive through IVF within a condensed timeframe. This synchronization leads to a higher likelihood of simultaneous calving among the cattle. While various synchronization methods already exist, Cetrorelix shows promise in potentially becoming the optimal choice in the near future.
By compressing the calving period, potentially from two months to one, producers can minimize labor costs and enhance animal management practices. This shortened timeframe could also result in higher weaning weights for calves, ultimately boosting the farmers’ profitability.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, the leading bovine reproduction center in Saskatchewan, expresses keen interest in integrating Cetrorelix into their operations. The drug’s introduction could improve artificial insemination methods, leading to enhanced genetic selection within herds and more accurate calf projection data.
Dr. Singh mentions that the university has filed for a patent for Cetrorelix and is collaborating with pharmaceutical companies to bring it to market. He envisions widespread adoption of artificial insemination practices globally, driven by the drug’s promising outcomes and its reasonable cost relative to industry standards.
The potential benefits of Cetrorelix extend beyond local farmers in Saskatchewan, with the drug holding promise for international adoption. Dr. Singh emphasizes the positive results seen in animals and the progress made in regulatory approval processes, indicating a strong potential for its successful implementation in the livestock industry.